Peptide Initiative

Peptides · Peptide comparison

Livagen vs Ventfort

Tetrapeptide bioregulator (Lys-Glu-Asp-Ala) that directly penetrates cell nuclei and binds double-stranded DNA to induce chromatin decondensation in senescent lymphocytes, activate ribosomal genes, inhibit enkephalin-degrading enzymes with an IC50 of 20 μM, and restore protein synthesis capacity in aging cells through selective epigenetic remodeling

Vascular peptide bioregulator complex derived from bovine aorta containing ultrashort peptides (including KED sequence) that normalize vascular endothelial function, reduce total cholesterol by up to 30% in clinical studies, and restore arterial elasticity through epigenetic regulation of extracellular matrix remodeling genes in aging blood vessels

  • Anti-Aging
  • Anti-Aging

At a glance

Quick comparison

Dose rangeLivagen5–10 mgVentfort2–2 capsules
FrequencyLivagenOnce dailyVentfortOnce daily
AdministrationLivagenIntramuscular injectionVentfortSublingual (enteric-coated capsules)
Cycle lengthLivagen8-12 weeksVentfort12+ weeks
Onset speedLivagenGradual (3-4 weeks)VentfortGradual (3-4 weeks)
Evidence levelLivagenLimited human trialsVentfortLimited human trials

Efficacy

Benefit ratings

Cell Renewal

Livagen94%
VentfortNo recorded rating

Liver Support

Livagen88%
VentfortNo recorded rating

DNA Protection

Livagen85%
VentfortNo recorded rating

Blood Vessel Health

LivagenNo recorded rating
Ventfort94%

Cholesterol Support

LivagenNo recorded rating
Ventfort88%

Heart Protection

LivagenNo recorded rating
Ventfort85%

Technical data

Compound specifications

Livagen

Molecular formula
C18H31N5O9
Molecular weight
461.5 g/mol
Half-life
Short plasma half-life typical of tetrapeptides; biological effects persist for weeks through epigenetic chromatin remodeling modifications; metabolized to constituent amino acids (lysine, glutamic acid, aspartic acid, alanine)
Bioavailability
Resistant to intestinal proteolysis when administered orally (weakly hydrolyzed by intestinal peptidases); efficient absorption from intramuscular injection sites; penetrates cytoplasmic and nuclear membranes to reach cell nuclei and nucleoli
CAS number
Not assigned (research compound)

Ventfort

Molecular formula
Complex peptide mixture (multiple sequences, MW range up to 5 kDa; active component KED: C13H22N4O7)
Molecular weight
Complex mixture up to 5,000 Da; KED active tripeptide: ~362.3 g/mol
Half-life
Short plasma half-life typical of ultrashort peptides (minutes to hours); biological effects persist for weeks to months through epigenetic modifications to vascular gene expression; metabolized to constituent amino acids
Bioavailability
Oral formulation absorbed via intestinal peptide transporters; ultrashort peptides in the complex have efficient cellular uptake; injectable form provides direct systemic delivery; tissue-derived peptides maintain bioactivity through enteric-coated capsule formulation
CAS number
Not applicable (tissue-derived complex)

Protocols

Dosing compared

Livagen

Intramuscular

  • 5-10 mgOnce daily · 10-day course (50-100 mg total)Reflects the Khavinson-laboratory bioregulator course used in practice: a total of 50-100 mg of the KEDA tetrapeptide delivered over 10 days. Livagen has no standardized human clinical dosing; evidence is largely preclinical [6].

Ventfort

Oral administration

  • 1 capsule (10 mg) once dailyOnce daily before meals · 10-day initial courseKhavinson A-3 vascular bioregulator (Ventfort); each capsule contains 10 mg peptide complex from vascular tissue [6]. Dietary-supplement form; research/wellness use.
  • 2 capsules (20 mg) dailyOnce or twice daily before meals · 10–20 day courseStandard daily dose (20 mg/day); courses typically repeated every 6 months [6]. Sublingual enteric-coated capsules used for buccal absorption.

Subcutaneous injection

  • 5–10 mgOnce daily · 10–20 day courseInjectable form of the A-3 complex for direct systemic delivery; same course length as oral [6]. Research use only.

Applications

Best suited for

Livagen

Comprehensive geroprotective therapy targeting epigenetic chromatin remodeling in aging cells
Livagen is particularly well-suited for individuals focused on comprehensive geroprotective therapy targeting epigenetic chromatin remodeling in aging cells. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting liver function and hepatoprotection in the context of aging
Livagen is particularly well-suited for individuals focused on supporting liver function and hepatoprotection in the context of aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Restoring protein synthesis and ribosomal function in elderly individuals
Livagen is particularly well-suited for individuals focused on restoring protein synthesis and ribosomal function in elderly individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Khavinson bioregulator protocols for anti-aging and longevity
Livagen is particularly well-suited for individuals focused on khavinson bioregulator protocols for anti-aging and longevity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Ventfort

Cardiovascular geroprotection — preserving vascular function during aging
Ventfort is particularly well-suited for individuals focused on cardiovascular geroprotection — preserving vascular function during aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Age-related arterial stiffness and endothelial dysfunction
Ventfort is particularly well-suited for individuals focused on age-related arterial stiffness and endothelial dysfunction. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Lipid profile optimization as adjunctive support alongside lifestyle modifications
Ventfort is particularly well-suited for individuals focused on lipid profile optimization as adjunctive support alongside lifestyle modifications. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting cardiovascular health
Ventfort is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting cardiovascular health. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

Livagen

Common

  • Injection site reaction
  • Mild fatigue
  • Mild headache
  • Digestive enzyme changes

Uncommon

  • Transient flu-like symptoms

Serious

  • No documented serious adverse effects

Ventfort

Common

  • Injection site reaction
  • Mild fatigue
  • Mild headache
  • Mild blood pressure fluctuation

Uncommon

  • Mild dizziness

Serious

  • No documented serious adverse effects

Research status

Safety & evidence

Livagen

Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Livagen (a liver-derived peptide extract) carries a safety profile established through decades of use in Eastern European hepatology and gastroenterology clinics. As an organ-derived extract rather than a synthetic single peptide, it contains multiple bioactive components promoting hepatocyte regeneration and cytoprotection. Adverse events are minimal in reported clinical experience—mild gastrointestinal upset occurring in <5% of patients. The compound shows no hepatotoxicity, nephrotoxicity, or immunosensitization in available safety surveillance data from thousands of patients.

Contraindications

  • Known hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, alanine)
  • Pregnancy and breastfeeding — insufficient reproductive safety data
  • Active autoimmune conditions in flare without physician supervision
  • Concurrent use of opioid medications — Livagen's enkephalinase inhibition may alter opioid metabolism

Ventfort

Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Ventfort (collagen peptide complex) demonstrates excellent safety profile from cosmetic and nutritional supplement use spanning decades. Hydrolyzed collagen peptides pass through the GI tract largely unchanged—minimal systemic absorption occurs, making serious adverse effects unlikely. Mild gastrointestinal side effects (bloating, dyspepsia) occur in <5% of users and are generally self-limiting. Allergic reactions are rare given the high molecular weight peptide fragments; histamine content is negligible in properly processed formulations.

Contraindications

  • Known hypersensitivity to bovine-derived peptide products or any constituent amino acids
  • Active bleeding disorders or concurrent anticoagulant therapy without medical supervision
  • Severe cardiovascular disease requiring immediate medical intervention
  • Pregnancy and breastfeeding — insufficient reproductive safety data

Decision guide

Which is right for you?

Livagen

Choose Livagen if…

  • Comprehensive geroprotective therapy targeting epigenetic chromatin remodeling in aging cells
  • Supporting liver function and hepatoprotection in the context of aging
  • Restoring protein synthesis and ribosomal function in elderly individuals
  • Khavinson bioregulator protocols for anti-aging and longevity

Ventfort

Choose Ventfort if…

  • Cardiovascular geroprotection — preserving vascular function during aging
  • Age-related arterial stiffness and endothelial dysfunction
  • Lipid profile optimization as adjunctive support alongside lifestyle modifications
  • Comprehensive Khavinson bioregulator protocols targeting cardiovascular health